Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers
Matthew Dankner, Emmanuelle Rousselle, Sarah Petrecca, François Fabi, Alexander Nowakowski, Anna-Maria Lazaratos, Charles Vincent Rajadurai, Andrew J. B. Stein, David Bian, Peter Tai, Alicia Belaiche, Meredith Li, Andrea Quaiattini, Nicola Normanno, Maria Arcila, Arielle Elkrief, Douglas B. Johnson, Marc Ladanyi, April A. N. Rose
medRxiv 2024.03.23.24304779; doi: https://doi.org/10.1101/2024.03.23.24304779